6 analysts have expressed a variety of opinions on Recursion Pharmaceuticals (NASDAQ:RXRX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 1 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 2 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $11.67, accompanied by a high estimate of $17.00 and a low estimate of $6.00. A decline of 15.62% from the prior average price target is evident in the current average.
![1725462034_0.png](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240904/47441226-0-43a4e2a5da2d1c37f4699b0ecab77da4.png/big)
Investigating Analyst Ratings: An Elaborate Study
The...
Login or create a forever free account to read this news
Sign up/Log in